In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Alcon AG agreed to acquire Staar Surgical Co. in a $1.5 billion cash transaction that would add Staar’s Evo implantable Collamer lenses (ICL) to treat myopia to the vision giant’s portfolio. Alcon ...

Lepu Biopharma Co. Ltd. has out-licensed two preclinical T-cell engagers to Shanghai-based newco Excalipoint in a deal worth ...

Neuroinflammation is a hallmark of Alzheimer’s disease (AD), driven in part by chronic microglial activation and elevated pro ...

Negotiations for the sixth U.S. FDA device user fee agreement (MDUFA VI) are officially underway, and the Aug. 4 meeting ...

Cassava Sciences Inc. a has reported positive preclinical results of a study evaluating simufilam in a mouse model of ...

Spine Biopharma Inc. cited an “inconsistent sham control response” among some of the sites in its phase III study testing ...

Good news bracketed July for Teleflex Inc. as it completed the acquisition of the vascular intervention business of ...

While inflation in the U.S. is hovering below 3%, increases in some FDA user fees for fiscal 2026 are tripling that rate.

Wavebreak Therapeutics LLC has identified thiazole compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of amyloidosis, Creutzfeldt-Jakob disease, ...